236 related articles for article (PubMed ID: 32227274)
1. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
Yuan J; Zou R; Zeng L; Kou S; Lan J; Li X; Liang Y; Ding X; Tan G; Tang S; Liu L; Liu Y; Pan Y; Wang Z
Inflamm Res; 2020 Jun; 69(6):599-606. PubMed ID: 32227274
[TBL] [Abstract][Full Text] [Related]
2. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Ding JG; Li J; Hong L; Yu XQ; Ye EL; Sun GQ; Zhang XX; Chen L; Sun QF
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5788-5796. PubMed ID: 32495917
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
5. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Zhu F; Cao Y; Xu S; Zhou M
J Med Virol; 2020 Jun; 92(6):529-530. PubMed ID: 32160316
[No Abstract] [Full Text] [Related]
6. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.
Huang Q; Deng X; Li Y; Sun X; Chen Q; Xie M; Liu S; Qu H; Liu S; Wang L; He G; Gong Z
Int J Clin Pharm; 2020 Jun; 42(3):837-845. PubMed ID: 32410206
[TBL] [Abstract][Full Text] [Related]
7. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
8. First patient management of COVID-19 in Changsha, China: a case report.
Zhou J; Cao Z; Wang W; Huang K; Zheng F; Xie Y; Jiang D; Zhou Z
BMC Infect Dis; 2020 Nov; 20(1):824. PubMed ID: 33176693
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
Lê MP; Jaquet P; Patrier J; Wicky PH; Le Hingrat Q; Veyrier M; Kauv J; Sonneville R; Visseaux B; Laouénan C; Bouadma L; Descamps D; de Montmollin E; Peytavin G; Timsit JF
J Antimicrob Chemother; 2020 Sep; 75(9):2657-2660. PubMed ID: 32688374
[TBL] [Abstract][Full Text] [Related]
10. The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
Liu JY; Hua MX; Du CJ; Pu L; Xiang P; Li CS; Xiong HF; Liu XZ; Chen ZH; Xie W; Li A
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11939-11944. PubMed ID: 33275267
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
Song J; Kang S; Choi SW; Seo KW; Lee S; So MW; Lim DH
Rheumatol Int; 2020 Jun; 40(6):991-995. PubMed ID: 32314010
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Wang B; Li D; Liu T; Wang H; Luo F; Liu Y
BMC Infect Dis; 2020 Oct; 20(1):723. PubMed ID: 33008327
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and treatment of COVID-19 patients in northeast Chongqing.
Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R
J Med Virol; 2020 Jul; 92(7):797-806. PubMed ID: 32198776
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China.
Zuo Y; Liu Y; Zhong Q; Zhang K; Xu Y; Wang Z
J Med Virol; 2020 Nov; 92(11):2666-2674. PubMed ID: 32492211
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
Wu H; Zhu H; Yuan C; Yao C; Luo W; Shen X; Wang J; Shao J; Xiang Y
JAMA Netw Open; 2020 Jun; 3(6):e2010895. PubMed ID: 32492165
[TBL] [Abstract][Full Text] [Related]
16. Treating COVID-19 with Chloroquine.
Huang M; Tang T; Pang P; Li M; Ma R; Lu J; Shu J; You Y; Chen B; Liang J; Hong Z; Chen H; Kong L; Qin D; Pei D; Xia J; Jiang S; Shan H
J Mol Cell Biol; 2020 May; 12(4):322-325. PubMed ID: 32236562
[No Abstract] [Full Text] [Related]
17. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
18. Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience.
Ahn MY; Oh DH; Kim S; Choi JP; Lee JH; Lee YK; Hong KH
Korean J Intern Med; 2020 Jul; 35(4):788-792. PubMed ID: 32668515
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 in a patient with pre-existing acute lymphoblastic leukaemia.
Wu Y; Lin H; Xie Q; Chen Q; Huang Y; Zhu Y; Chen L
Br J Haematol; 2020 Jul; 190(1):e13-e15. PubMed ID: 32379902
[No Abstract] [Full Text] [Related]
20. [Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
Li T; Deng C; Du Q; Yue R; Lu S; Chen H; Guo Y; Huang X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Aug; 32(8):928-932. PubMed ID: 32912404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
